These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 12379846

  • 1. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.
    Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM.
    Nat Med; 2002 Nov; 8(11):1270-5. PubMed ID: 12379846
    [Abstract] [Full Text] [Related]

  • 2. [Specific humoral immune response in Rhesus monkeys vaccinated immune response with Abeta42 peptide vaccine].
    Li SB, Wang HQ, Lin X, Xu J, Yao ZB.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):202-4. PubMed ID: 15766406
    [Abstract] [Full Text] [Related]

  • 3. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
    Kulic L, Kurosinski P, Chen F, Tracy J, Mohajeri MH, Li H, Nitsch RM, Götz J.
    Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
    [Abstract] [Full Text] [Related]

  • 4. [Immunologic tolerance of anti-Abeta antibody in the sera of AD patients].
    Yang ZY, Wang HQ, Xu J, Xie Y, Yuan QF, Yao ZB.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Oct; 23(10):929-31. PubMed ID: 17908502
    [Abstract] [Full Text] [Related]

  • 5. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.
    McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P.
    Nat Med; 2002 Nov; 8(11):1263-9. PubMed ID: 12379850
    [Abstract] [Full Text] [Related]

  • 6. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V, Steinitz M.
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [Abstract] [Full Text] [Related]

  • 7. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model.
    Matsuda J, Kaminaka K, Nozaki C.
    Biochem Biophys Res Commun; 2009 Apr 24; 382(1):149-52. PubMed ID: 19265678
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.
    Brain; 2008 Dec 24; 131(Pt 12):3299-310. PubMed ID: 18953056
    [Abstract] [Full Text] [Related]

  • 10. Lessons from the AN 1792 Alzheimer vaccine: lest we forget.
    Robinson SR, Bishop GM, Lee HG, Münch G.
    Neurobiol Aging; 2004 Dec 24; 25(5):609-15. PubMed ID: 15172738
    [Abstract] [Full Text] [Related]

  • 11. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
    Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M.
    Brain Res; 2008 Jul 11; 1219():169-79. PubMed ID: 18534566
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A, Döbeli H, Bohrmann B.
    Neuroscience; 2006 Dec 01; 143(2):461-75. PubMed ID: 17008022
    [Abstract] [Full Text] [Related]

  • 14. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
    Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM.
    Neuron; 2004 Aug 05; 43(3):321-32. PubMed ID: 15294141
    [Abstract] [Full Text] [Related]

  • 15. Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed.
    Hutton M, McGowan E.
    Neuron; 2004 Aug 05; 43(3):293-4. PubMed ID: 15294135
    [Abstract] [Full Text] [Related]

  • 16. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice.
    Bach P, Tschäpe JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, Staufenbiel M, Prinz M, Deller T, Kalinke U, Buchholz CJ, Müller UC.
    J Immunol; 2009 Jun 15; 182(12):7613-24. PubMed ID: 19494285
    [Abstract] [Full Text] [Related]

  • 17. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology.
    Attems J, Lintner F, Jellinger KA.
    Acta Neuropathol; 2004 Apr 15; 107(4):283-91. PubMed ID: 14986026
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of Alzheimer disease: A beta vaccine].
    Tabira T, Hara H.
    Rinsho Shinkeigaku; 2004 Nov 15; 44(11):778-80. PubMed ID: 15651289
    [Abstract] [Full Text] [Related]

  • 19. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
    Jensen MT, Mottin MD, Cracchiolo JR, Leighty RE, Arendash GW.
    Neuroscience; 2005 Nov 15; 130(3):667-84. PubMed ID: 15590151
    [Abstract] [Full Text] [Related]

  • 20. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.
    Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der Auwera I, van Leuven F, Sugawara M, Weingertner MC, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C.
    Proc Natl Acad Sci U S A; 2007 Jun 05; 104(23):9810-5. PubMed ID: 17517595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.